Publications by authors named "Gaelle Asset"

Claim this Profile
I
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Meletios A Dimopoulos, Philippe Moreau, Bradley Augustson, Nelson Castro, Tomas Pika, Gaelle Asset

Am J Hematol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
Thierry Facon, Philippe Moreau, Thomas G Martin, Ivan Spicka, Albert Oriol, Gaëlle Asset

Hematol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
Ivan Spicka, Philippe Moreau, Thomas G Martin, Thierry Facon, Gracia Martinez, Gaëlle Asset

Eur J Haematol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
Thomas Martin, Joseph Mikhael, Roman Hajek, Kihyun Kim, Kenshi Suzuki, Gaelle Asset

Blood Adv· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Philippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Gaelle Asset

Lancet· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design.
Philippe Moreau, Meletios A Dimopoulos, Kwee Yong, Joseph Mikhael, Marie-Laure Risse, Gaëlle Asset

Future Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years.
Michel Farnier, Helen M Colhoun, William J Sasiela, Jay M Edelberg, Gaëlle Asset

J Clin Lipidol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
Eli M Roth, James M McKenney, Corinne Hanotin, Gaelle Asset, Evan A Stein

N Engl J Med· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis